37 New Rheometer Installed in New GMP Testing Facility at NMI Reutlingen
Researchers at the Natural and Medical Sciences Institute (NMI) at the University of Tübingen in Germany have installed a Kinexus rheometer from Malvern Instruments in the new GMP testing facility at its subsidiary, NMI Technologietransfer GmbH. The Kinexus is used primarily for the characterisation of biomaterials, mainly hydrogels containing patient cells. Such hydrogels are used as a stabilising 3D-matrix for innovative cell therapeutics in the exciting field of regenerative medicine, targeting for example the regeneration of articular cartilage, spinal discs and injured nerves.
Regenerative medicine is a core competence and a key focus for various research groups within the NMI. The advent of new and more stringent regulation of the materials used in regenerative medicine now subjects them to controls similar to those applied for pharmaceutical products. To meet the need for pharmaceutical-type testing, NMI has established a new GMP facility at its subsidiary, NMI Technologietransfer GmbH, to enable the fully regulated testing both of regenerative materials and the biomaterials necessary for their delivery.
Professor Dr Dieter Stoll, head of quality control in the new GMP facility, is particularly pleased with the support provided by the Malvern team who recently ran a workshop specifically for the five people who will be regular users of the Kinexus. “Our users range from people who are very experienced to others who are not expert rheologists, so some were initially a little nervous about using the rheometer,” he said. “However, the workshop was perfect. Everyone was able to go to the machine and use it, gain confidence and discuss different items with the Malvern team.”
Kinexus is a unique rheometer from Malvern Instruments designed to meet rheology needs across a wide variety of research sectors, industries and application
areas, for users at every level of experience. It enables precise analysis of the rheology of materials: from liquids to soft solids, processability to product performance, temperature to time dependence.
Circle no. 140
Highly Efficient, Reproducible Non-Cytotoxic Transfection Reagent GenePORTER®
transfection of a wide variety of cell lines.
Molecular target delivery faces many barriers, from crossing the cell type-specific extracellular membrane, to cytoplasmic degradation and translocation across the nuclear membrane. To be effective, the transfection reagent/DNA complexes must overcome all of these challenges whilst minimising cytotoxicity.
Traditionally the most efficient delivery methods have also been the most cytotoxic. Using Advanced Carrier Enhancement technology, a nuclear targeting mechanism that maximises transfection and transgene expression levels while still maintaining high cell viability, GenePORTER®
Gold has been able to address this limitation. Based on generations of proven cationic lipid formulations with more than 850 citations to date, GenePORTER® Gold
uniquely combines consistent delivery and reliability with the lowest reported cytotoxicity of commercially available transfection reagents.
The GenePORTER® Gold protocol has been optimised to provide simple, same-day transfection making it ideal for high throughput or large scale applications where the need for consistent results is highly desirable. Circle no. 141
Gold from Amsbio is a new highly efficient and reproducible lipid-based reagent for effective
Anytime, Anywhere...
WE HELP YOU SLEEP AT NIGHT: XILTRIX
MONITORING SYSTEMS.
Sleep soundly knowing that your precious samples are safe, watched over by your XiltriX®
Labmate-online.com |
info@iksbv.com
laboratory monitoring system. Multiple
parameters in multiple locations, measured, logged and, just in case, alarmed.
www.iksinternational.nl
Circle no. 142 Circle no. 143
INTERNATIONAL LABMATE - MARCH 2011 - LABORATORY PRODUCTS
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
